相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Broad-spectrum Preclinical Antitumor Activity of Eribulin (Halaven®): Combination with Anticancer Agents of Differing Mechanisms
Makoto Asano et al.
ANTICANCER RESEARCH (2018)
Multiple modes of action of eribulin mesylate: Emerging data and clinical implications
Javier Cortes et al.
CANCER TREATMENT REVIEWS (2018)
The Effect of Everolimus in an In Vitro Model of Triple Negative Breast Cancer and Osteoclasts
Laura Mercatali et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)
Eribulin synergizes with Polo-like kinase 1 inhibitors to induce apoptosis in rhabdomyosarcoma
Angelika Stehle et al.
CANCER LETTERS (2015)
Baicalein upregulates DDIT4 expression which mediates mTOR inhibition and growth inhibition in cancer cells
Yujun Wang et al.
CANCER LETTERS (2015)
Eribulin Mesylate: Mechanism of Action of a Unique Microtubule-Targeting Agent
Nicholas F. Dybdal-Hargreaves et al.
CLINICAL CANCER RESEARCH (2015)
Synergistic anti-tumor effect of combined inhibition of EGFR and JAK/STAT3 pathways in human ovarian cancer
Wei Wen et al.
MOLECULAR CANCER (2015)
Everolimus Plus Exemestane for the Treatment of Advanced Breast Cancer: A Review of Subanalyses from BOLERO-2
Gabriel N. Hortobagyi
NEOPLASIA (2015)
Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer
Jasmeet Chadha Singh et al.
BREAST CANCER RESEARCH (2014)
Microtubule dynamics regulates Akt signaling via dynactin p150
Hakryul Jo et al.
CELLULAR SIGNALLING (2014)
Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors
Rodrigo Dienstmann et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Triple-Negative Breast Cancer Patients Treated at MD Anderson Cancer Center in Phase I Trials: Improved Outcomes with Combination Chemotherapy and Targeted Agents
Prasanth Ganesan et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Suppression of Feedback Loops Mediated by PI3K/mTOR Induces Multiple Overactivation of Compensatory Pathways: An Unintended Consequence Leading to Drug Resistance
Enrique Rozengurt et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Triple-Negative Breast Cancer and the Need for New Therapeutic Targets
Olav Engebraaten et al.
AMERICAN JOURNAL OF PATHOLOGY (2013)
Molecular and Cellular Heterogeneity in Breast Cancer Challenges for Personalized Medicine
Ashley G. Rivenbark et al.
AMERICAN JOURNAL OF PATHOLOGY (2013)
Targeted Therapy for Breast Cancer
Ali Mohamed et al.
AMERICAN JOURNAL OF PATHOLOGY (2013)
Functional proteomics characterization of residual triple-negative breast cancer after standard neoadjuvant chemotherapy
J. Sohn et al.
ANNALS OF ONCOLOGY (2013)
Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer
A. M. Gonzalez-Angulo et al.
CANCER TREATMENT REVIEWS (2013)
Novel Approaches for Molecular Targeted Therapy of Breast Cancer: Interfering with PI3K/AKT/mTOR Signaling
Thomas W. Grunt et al.
CURRENT CANCER DRUG TARGETS (2013)
A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer
K. Aogi et al.
ANNALS OF ONCOLOGY (2012)
Chemotherapy-Resistant Metastatic Breast Cancer
Carrie Marquette et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2012)
The BOLERO-2 trial: the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer
Julia A. Beaver et al.
FUTURE ONCOLOGY (2012)
Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study
Thomas Bachelot et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer
Jose Baselga et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Rapamycin and mTOR: a serendipitous discovery and implications for breast cancer
Belinda Seto
CLINICAL AND TRANSLATIONAL MEDICINE (2012)
Eribulin Induces Irreversible Mitotic Blockade: Implications of Cell-Based Pharmacodynamics for In vivo Efficacy under Intermittent Dosing Conditions
Murray J. Towle et al.
CANCER RESEARCH (2011)
Phase I/II Study of Trastuzumab in Combination With Everolimus (RAD001) in Patients With HER2-Overexpressing Metastatic Breast Cancer Who Progressed on Trastuzumab-Based Therapy
Phuong K. Morrow et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Phosphatidylinositol 3-Kinase and Antiestrogen Resistance in Breast Cancer
Todd W. Miller et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
Javier Cortes et al.
LANCET (2011)
Eribulin Binds at Microtubule Ends to a Single Site on Tubulin To Suppress Dynamic Instability
Jennifer A. Smith et al.
BIOCHEMISTRY (2010)
Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method
Ting-Chao Chou
CANCER RESEARCH (2010)
Biomarkers and Patient Selection for PI3K/Akt/mTOR Targeted Therapies: Current Status and Future Directions
John M. S. Bartlett
CLINICAL BREAST CANCER (2010)
Deciphering the Role of PI3K/Akt/mTOR Pathway in Breast Cancer Biology and Pathogenesis
Priscilla F. McAuliffe et al.
CLINICAL BREAST CANCER (2010)
Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways
Sandra E. Ghayad et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Phase II Study of the Halichondrin B Analog Eribulin Mesylate in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane, and Capecitabine
Javier Cortes et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Triple-Negative Breast Cancer
William D. Foulkes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Loss of Phosphatase and Tensin Homologue Deleted on Chromosome 10 Engages ErbB3 and Insulin-Like Growth Factor-I Receptor Signaling to Promote Antiestrogen Resistance in Breast Cancer
Todd W. Miller et al.
CANCER RESEARCH (2009)
Tubulin acetylation favors Hsp90 recruitment to microtubules and stimulates the signaling function of the Hsp90 clients Akt/PKB and p53
Julien Giustiniani et al.
CELLULAR SIGNALLING (2009)
A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies
Sanjay Goel et al.
CLINICAL CANCER RESEARCH (2009)
Phase I Study of Eribulin Mesylate Administered Once Every 21 Days in Patients with Advanced Solid Tumors
Antoinette R. Tan et al.
CLINICAL CANCER RESEARCH (2009)
Phase II Study of Eribulin Mesylate, a Halichondrin B Analog, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
Linda T. Vahdat et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation
Xuerong Wang et al.
CANCER RESEARCH (2008)
Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase
Tatiana Okouneva et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients
David S. P. Tan et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer
Katrien Berns et al.
CANCER CELL (2007)
The PI3K-Akt pathway promotes microtubule stabilization in migrating fibroblasts
Keisuke Onishi et al.
GENES TO CELLS (2007)
Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism
X. Wan et al.
ONCOGENE (2007)
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
KE O'Reilly et al.
CANCER RESEARCH (2006)
Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition
SY Sun et al.
CANCER RESEARCH (2005)
The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth
MA Jordan et al.
MOLECULAR CANCER THERAPEUTICS (2005)
A phase I pharmacokinetic and target validation study of the novel anti-tubulin agent E7389: A California Cancer Consortium trial.
TW Synold et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389
G Kuznetsov et al.
CANCER RESEARCH (2004)
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
Y Nagata et al.
CANCER CELL (2004)
Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients
G Pérez-Tenorio et al.
BRITISH JOURNAL OF CANCER (2002)
The multiple roles of PTEN in tumor suppression
A Di Cristofano et al.
CELL (2000)
分享论文
